These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 11606371

  • 1. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
    Murillo H, Schmidt LJ, Tindall DJ.
    Cancer Res; 2001 Oct 15; 61(20):7408-12. PubMed ID: 11606371
    [Abstract] [Full Text] [Related]

  • 2. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways.
    Kraus S, Levy G, Hanoch T, Naor Z, Seger R.
    Cancer Res; 2004 Aug 15; 64(16):5736-44. PubMed ID: 15313914
    [Abstract] [Full Text] [Related]

  • 3. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C.
    Cancer Res; 2002 Nov 01; 62(21):6039-44. PubMed ID: 12414626
    [Abstract] [Full Text] [Related]

  • 4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 5. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L, Chang C.
    Cancer Res; 2003 Nov 01; 63(21):7106-12. PubMed ID: 14612503
    [Abstract] [Full Text] [Related]

  • 6. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 7. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
    Engedal N, Korkmaz CG, Saatcioglu F.
    Oncogene; 2002 Feb 07; 21(7):1017-27. PubMed ID: 11850819
    [Abstract] [Full Text] [Related]

  • 8. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
    Ou YC, Yang CR, Cheng CL, Raung SL, Hung YY, Chen CJ.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):49-60. PubMed ID: 17341418
    [Abstract] [Full Text] [Related]

  • 9. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells.
    Uzgare AR, Isaacs JT.
    Cancer Res; 2004 Sep 01; 64(17):6190-9. PubMed ID: 15342404
    [Abstract] [Full Text] [Related]

  • 10. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: therapeutic implications for prostate cancer.
    Joo SS, Yoo YM.
    J Pineal Res; 2009 Aug 01; 47(1):8-14. PubMed ID: 19522739
    [Abstract] [Full Text] [Related]

  • 11. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.
    Endocr Relat Cancer; 2005 Mar 01; 12(1):119-34. PubMed ID: 15788644
    [Abstract] [Full Text] [Related]

  • 12. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH, Song YC, Kim SH, Jo H, Song YS.
    Ann N Y Acad Sci; 2009 Aug 01; 1171():642-8. PubMed ID: 19723115
    [Abstract] [Full Text] [Related]

  • 13. Leuprorelin acetate affects ERK1/2 activity in prostate cancer cells.
    Iacopino F, Lama G, Angelucci C, Sica G.
    Int J Oncol; 2006 Jul 01; 29(1):237-47. PubMed ID: 16773205
    [Abstract] [Full Text] [Related]

  • 14. c-Myc potentiates the mitochondrial pathway of apoptosis by acting upstream of apoptosis signal-regulating kinase 1 (Ask1) in the p38 signalling cascade.
    Desbiens KM, Deschesnes RG, Labrie MM, Desfossés Y, Lambert H, Landry J, Bellmann K.
    Biochem J; 2003 Jun 01; 372(Pt 2):631-41. PubMed ID: 12646044
    [Abstract] [Full Text] [Related]

  • 15. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism.
    Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A.
    Carcinogenesis; 2008 Jul 01; 29(7):1334-42. PubMed ID: 18566014
    [Abstract] [Full Text] [Related]

  • 16. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells.
    Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF.
    Oncogene; 2003 Feb 06; 22(5):781-96. PubMed ID: 12569372
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 18. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 19. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
    Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ.
    Cancer Res; 2004 Jul 01; 64(13):4394-9. PubMed ID: 15231645
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R.
    Mol Carcinog; 2004 Nov 01; 41(3):164-78. PubMed ID: 15390078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.